How to find and design bioactive peptides at scale?

How to find and design bioactive peptides at scale?

Research Question and Applicant Fit

Can a defined group of plant-derived cyclic peptides be studied at enough scale to connect molecular diversity with reproducible biological effects? This doctorate links computational, molecular and behavioural evidence. Its ambition is to build a useful research dataset and platform, not to establish that any peptide is already an oral treatment or pesticide.

The saved LMS four-year recruitment record lists “How to find and design bioactive peptides at scale?” with Karen Sarkisyan, David Craik and Andre Brown. The project description covers a selected cyclic-peptide group, production and biological assessment, biochemical characterisation and a prospective AI-guided design platform. These are advertised research aims, not completed resources or a validated clinical outcome. Eligibility for the competitive LMS award is distinct from receiving it. LMS recruitment page, official project DOCX.

Research Direction and Doctoral Scope

The project combines computational library work, synthetic biology, heterologous production, biochemical characterisation and automated animal phenotyping. It is not a purely computational design doctorate. The question is how natural peptide diversity relates to biological effects, what those observations can support about mechanism, and whether the resulting dataset can inform later computational research.

The advertised ambition covers all known natural sequences within one selected group of plant-derived cyclic peptides, not all plant peptides. C. elegans development and behaviour provide the initial biological context; activity in a model organism does not establish effects in a pest or parasitic species, and neither establishes human oral efficacy. Follow-up biological and mechanistic questions remain part of the research, not guaranteed transfer between species.

The scope is broad. Confirm what material and data already exist, what the student will own, how evidence quality will be judged and how work across the groups will fit a doctoral timescale. The aim is to clarify a feasible thesis rather than assume an industrial-scale platform is ready.

University and programme signal

The project sits in LMS/Imperial's biomedical research environment but includes a major international collaboration with David Craik's University of Queensland group. LMS students are enrolled through Imperial College London's Faculty of Medicine, which gives Imperial doctoral status and training access. Imperial's ranking signal and LMS's institute facilities support the environment, while UQ/IMB adds specialist peptide expertise rather than degree-awarding status. Sources: LMS studentships overview, Imperial league tables, UQ Craik group.

The advertised collaboration brings together molecular research, biochemical interpretation, quantitative phenotyping and computational work. The exact programme of compulsory training, progress assessments and cross-laboratory supervision is not given in the saved description. Clarify these arrangements and any UQ visit; collaboration does not itself create a joint degree, funded visit or personal facility allocation.

Supervisor and lab assessment

Karen Sarkisyan's official Synthetic Biology group page is a close match. It describes protein design for therapeutics and crop protection, synthetic biology, high-throughput assays, automation, bacterial and plant systems, and animal-model testing. That supports the project’s ambition to move beyond purely computational peptide design into production and in vivo screening. Source: Synthetic Biology group.

Andre Brown's Behavioural Phenomics group supplies the C. elegans high-throughput phenotyping backbone. The official group page describes imaging, machine learning, molecular perturbations, rare-disease and drug-repurposing models, and very high-throughput behaviour assays. This is important because the project's first screen depends on robust worm development/behaviour readouts. Source: Behavioural Phenomics group.

David Craik is the key cyclic-peptide collaborator. The UQ IMB profile identifies him as a leading cyclotide and cyclic-peptide researcher, with work on stable plant-derived cyclic peptides for drug and agrichemical design. His involvement increases topic credibility, but applicants should verify whether supervision is remote, whether travel to Australia is expected or funded, and who controls peptide chemistry decisions day to day. Source: UQ Craik group.

Recent publications and research quality

Molecular tools and data-platform evidence

Sarkisyan's recent publications show platform-building strength. A 2024 Nature Methods paper on autonomous bioluminescence imaging in eukaryotes and a 2024 Science Advances paper on hybrid self-sustained luminescence show molecular-tool engineering. A 2022 eLife paper connects a large GFP fitness landscape to data-driven protein research, relevant to the project’s computational aspect. These molecular-tool examples do not themselves validate a cyclic-peptide platform or cross-species biological effects. Sources: Nature Methods 2024, Science Advances 2024, eLife 2022.

Behavioural phenotyping and peptide-field context

Brown's work provides behavioural-phenotyping context. His group page and related papers show high-throughput C. elegans phenotyping and behavioural fingerprints that can predict insecticide and anthelmintic mode of action. Craik-linked 2024 cyclotide work provides peptide-chemistry context. The separately cited 2024 oral-bioavailability study is wider field evidence; no unverified author attribution to Craik is made. Neither context proves that the project’s selected peptide group will have transferable activity or oral efficacy. Sources: high-throughput C. elegans tracking, behavioural fingerprints MSB, grafted cyclotides 2024, orally bioavailable cyclic peptides 2024.

Funding, costs and living feasibility

The official LMS funding page states all nationalities may apply and that successful students receive £26,500 tax-free per year for four years, tuition fees, necessary research consumables and overseas visa costs. It gives 18 November 2026 at 09:00 as the deadline. The page omits the time zone; the saved application form specifies 9am UK time. Reference deadlines should be checked separately. Source: LMS recruitment page.

The LMS package is strong for international applicants: stipend, full tuition, consumables and overseas visa costs for successful students. It does not automatically guarantee project-specific costs such as Australia travel, large-scale synthesis, commercial screening consumables or cloud/compute. London costs remain significant; applicants should budget rent, deposits, travel and any unfunded collaboration visit. The stated overseas visa support does not settle IHS, dependant costs or payment timing, which need written clarification. Sources: LMS recruitment page, Imperial living costs.

Chinese/international eligibility and fit

The official page says all nationalities can apply. Chinese applicants are eligible in principle if they meet Imperial/LMS academic and English requirements and can show research fit. Existing LMS admission information requires an obtained or expected first-class or upper-second-class degree or equivalent in a relevant scientific subject from a recognised university. A relevant master’s is preferred; equivalent research experience totalling at least one year may also be considered. The examples below are possible preparation, not a requirement to already know every technique.

Best-fit backgrounds include synthetic biology, molecular biology, protein engineering, peptide chemistry, bioinformatics, C. elegans biology, assay automation, machine learning for sequences, or biochemical screening. A pure AI applicant should show wet-lab collaboration literacy; a pure wet-lab applicant should show quantitative or programming readiness. Sources: LMS recruitment page, Imperial international qualifications guidance, Imperial English requirements.

Because the project touches bioactive molecules, pest/parasitic species and AI-guided design, applicants should ask about biosecurity, export-control, IP and data-sharing boundaries. No China-specific exclusion was found in the official evidence, but security review can depend on exact materials, species, data and collaboration terms.

Career and risk assessment

Training may be relevant to synthetic biology, peptide therapeutic research, agri-biotech, bioactive natural products, phenotyping, computational protein research and biotech platform roles. These are possible directions rather than measured employment outcomes for this project. UK life-sciences market evidence and biological-security strategy both suggest demand for people who can combine biology, data and responsible engineering. The main risk is operational: a PhD student may be stretched across peptide production, worm screening, mechanism assays and AI modelling without a clearly owned thesis core. Sources: UK life sciences indicators, UK Life Sciences Jobs Plan, UK Biological Security Strategy.

Application Route and Timing

The saved LMS application form, page 1, specifies 9am UK time for the 18 November deadline. The existing brief directs applicants to send the completed form to students@lms.mrc.ac.uk, supply two academic referees and ask them to send references directly. Registering interest is not an application. The retained planned intake is 4 October 2027; confirm the personal start and whether references share the application cutoff. Official application form.

Verification questions

1. The application form confirms 9am UK time; check whether references share the same cutoff.
2. Ask which plant-derived cyclic-peptide group is selected and how many natural sequences are in scope.
3. Confirm the readiness of starting resources, the student-owned research scope and how molecular and behavioural evidence will be interpreted.
4. Ask which pest or parasitic species are likely follow-up models and what ethics/biosafety approvals apply.
5. Confirm the computational/AI methods, dataset ownership and publication/IP terms across LMS, Imperial and UQ.
6. Ask whether international travel to UQ, peptide synthesis costs, compute and commercialisation/IP costs are funded.
7. Ask whether ATAS, export-control or biosecurity checks apply for Chinese applicants.

Evidence and sources

The saved LMS recruitment page lists 18 November 2026 but does not specify a time zone; the saved 2026–27 application form (page 1) specifies 09:00 UK time (Europe/London). Whether references share the cutoff is unconfirmed. The saved materials do not establish whether applications are currently being accepted, so they support neither a claim of present openness nor closure. Publication summaries retain the earlier reports’ high-level descriptions; complete ordered bylines, individual author roles and full-text/supplement access are not established for every cited item.

Key sources include the LMS recruitment page, official Sarkisyan project DOCX, Synthetic Biology group, Behavioural Phenomics group, UQ Craik group, Nature Methods 2024, Science Advances 2024, eLife 2022, behavioural fingerprints MSB, grafted cyclotides 2024 and Imperial living costs.

• Current LMS 2026–27 application form: 9am UK time.